About Compremium AG

Compremium develops non-invasive medical devices for diagnosing pressure-related health conditions. Their technology provides precise and actionable diagnostic data, enabling healthcare professionals to make informed decisions for early detection and improved patient outcomes.

```xml <problem> Diagnosing pressure-related conditions such as compartment syndrome, edema, and venous insufficiency often relies on invasive methods or subjective assessments, leading to delayed diagnoses and potentially suboptimal patient outcomes. Current diagnostic approaches may lack the precision and objectivity needed for early detection and effective management of these conditions. </problem> <solution> Compremium provides non-invasive medical devices that offer precise and actionable diagnostic data for pressure-related health conditions. Their technology enables clinicians to objectively measure tissue compressibility and occlusion pressure, facilitating early and accurate diagnoses at the point of care. The CPMX1 system is FDA-cleared for soft tissue management, while the CPMX2 system is for investigational use in vascular assessments. By providing quantitative, reliable data, Compremium's solutions aim to improve clinical decision-making, enhance patient outcomes, and transform traditional diagnostic pathways. The devices are designed for seamless integration into clinical workflows and are being developed with AI capabilities, EHR connectivity, and telemedicine compatibility. </solution> <features> - Non-invasive measurement of tissue compressibility and occlusion pressure - CPMX1: FDA-cleared device for diagnosing and managing soft tissue injuries - CPMX2: Investigational device for measuring pressure in vessels for diagnosing vascular conditions - Real-time measurements in under 30 seconds - Trend tracking and pattern analysis for predictive diagnoses - High reliability and reproducibility (Interclass Correlation Coefficient of 0.911 for CPMX1 measurements) - AI-enabled features for simplicity and consistency (under development, currently for investigational use only) - EHR connectivity for improved workflows and patient outcomes (under development, currently for investigational use only) - Telemedicine compatibility for remote diagnostics (under development, currently for investigational use only) - Secure data storage - Long-lasting battery life - Intuitive touchscreen interface - MIL-STD 810H compliant combat solution available </features> <target_audience> The primary target audience includes physicians in clinics and hospitals needing objective diagnostic tools for pressure-related conditions, as well as military medical personnel requiring ruggedized diagnostic solutions for austere environments. </target_audience> ```

What does Compremium AG do?

When was Compremium AG founded?

Compremium AG was founded in 2020.

How much funding has Compremium AG raised?

Compremium AG has raised $50.0K.

Founded

2020

Funding

$50.0K

Employees

17 employees

Major Investors

Additional Ventures

Compremium AG

Founded 2020171K+ followers9/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.

Updated 16 months ago

Funding

$50.0K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Diagnosing pressure-related conditions such as compartment syndrome, edema, and venous insufficiency often relies on invasive methods or subjective assessments, leading to delayed diagnoses and potentially suboptimal patient outcomes. Current diagnostic approaches may lack the precision and objectivity needed for early detection and effective management of these conditions.

Solution

Compremium provides non-invasive medical devices that offer precise and actionable diagnostic data for pressure-related health conditions. Their technology enables clinicians to objectively measure tissue compressibility and occlusion pressure, facilitating early and accurate diagnoses at the point of care. The CPMX1 system is FDA-cleared for soft tissue management, while the CPMX2 system is for investigational use in vascular assessments. By providing quantitative, reliable data, Compremium's solutions aim to improve clinical decision-making, enhance patient outcomes, and transform traditional diagnostic pathways. The devices are designed for seamless integration into clinical workflows and are being developed with AI capabilities, EHR connectivity, and telemedicine compatibility.

Target Audience

The primary target audience includes physicians in clinics and hospitals needing objective diagnostic tools for pressure-related conditions, as well as military medical personnel requiring ruggedized diagnostic solutions for austere environments.

Features

Non-invasive measurement of tissue compressibility and occlusion pressure
CPMX1: FDA-cleared device for diagnosing and managing soft tissue injuries
CPMX2: Investigational device for measuring pressure in vessels for diagnosing vascular conditions
Real-time measurements in under 30 seconds
Trend tracking and pattern analysis for predictive diagnoses
High reliability and reproducibility (Interclass Correlation Coefficient of 0.911 for CPMX1 measurements)
AI-enabled features for simplicity and consistency (under development, currently for investigational use only)
EHR connectivity for improved workflows and patient outcomes (under development, currently for investigational use only)
Telemedicine compatibility for remote diagnostics (under development, currently for investigational use only)
Secure data storage
Long-lasting battery life
Intuitive touchscreen interface
MIL-STD 810H compliant combat solution available